Crystallization of 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903,11]-dodecane
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07D-255/00
C06B-025/34
C06B-025/00
출원번호
US-0042522
(2002-01-09)
발명자
/ 주소
Hamilton,R. Scott
출원인 / 주소
Alliant Techsystems Inc.
대리인 / 주소
TraskBritt
인용정보
피인용 횟수 :
0인용 특허 :
13
초록▼
A method is provided in which 2,4,6,8,10,12-hexanitro-2,4,6, 8,10,12-hexaazatetracyclo[5.5.0.05,903, 11]-dodecane (CL-20 or HNIW) is crystallized to its ε-polymorph by an inverse precipitation technique. A dry CL-20 solvent solution containing an amount of CL-20 dissolved in a CL-20 solvent is
A method is provided in which 2,4,6,8,10,12-hexanitro-2,4,6, 8,10,12-hexaazatetracyclo[5.5.0.05,903, 11]-dodecane (CL-20 or HNIW) is crystallized to its ε-polymorph by an inverse precipitation technique. A dry CL-20 solvent solution containing an amount of CL-20 dissolved in a CL-20 solvent is prepared. The dry solvent solution is added to a crystallizer containing a CL-20 non-solvent to cause precipitation of epsilon polymorph CL-20 crystals by the inverse precipitation technique. The precipitated epsilon polymorph CL-20 crystals are separated from the non-solvent and the solvent.
대표청구항▼
What is claimed is: 1. A method for crystallizing epsilon polymorph 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903, 11]-dodecane (CL-20), comprising: preparing a substantially dry CL-20 solvent solution containing an amount of CL-20 dissolved in a CL-20 solvent; providing a c
What is claimed is: 1. A method for crystallizing epsilon polymorph 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903, 11]-dodecane (CL-20), comprising: preparing a substantially dry CL-20 solvent solution containing an amount of CL-20 dissolved in a CL-20 solvent; providing a crystallizer containing a CL-20 non-solvent; adding the substantially dry solvent solution to the crystallizer containing the CL-20 non-solvent to cause precipitation of epsilon polymorph CL-20 crystals by inverse precipitation technique; and separating the precipitated epsilon polymorph CL-20 crystals from the CL-20 non-solvent and the CL-20 solvent. 2. The method according to claim 1, wherein preparing the substantially dry CL-20 solvent solution comprises substantially drying a wet CL-20 solvent solution containing the amount of CL-20 dissolved in the CL-20 solvent. 3. The method according to claim 2, wherein substantially drying the wet CL-20 solvent solution comprises azeotropic distillation to remove an azeotrope comprising water and the CL-20 solvent. 4. The method according to claim 1, wherein the substantially dry CL-20 solvent solution contains less than 1.5 weight percent water. 5. The method according to claim 1, wherein the CL-20 solvent comprises at least one member selected from the group consisting of ethyl acetate, methyl acetate, isopropyl acetate, butyl acetate, tetrahydrofuran, and methyl ethyl ketone. 6. The method according to claim 1, wherein the CL-20 solvent comprises ethyl acetate. 7. The method according to claim 1, wherein the solubility of CL-20 in the CL-20 solvent is greater than 20 percent weight/volume (g/ml) . 8. The method according to claim 1, wherein the CL-20 non-solvent is free of halogens. 9. The method according to claim 1, wherein the CL-20 non-solvent is free of chlorine. 10. The method according to claim 1, wherein the CL-20 non-solvent comprises at least one member selected from the group consisting of hexane, cycloheptane, heptane, octane, benzene, toluene, and xylene. 11. The method according to claim 1, wherein separating the precipitated epsilon polymorph CL-20 crystals from the non-solvent and the solvent comprises filtration. 12. The method according to claim 1, wherein the precipitated epsilon polymorph CL-20 crystals comprise particles having maximum diameters of, on average, about 40 μ m to about 70 μm. 13. The method according to claim 1, further comprising adding a co-non-solvent to a wet CL-20 solvent solution or the substantially dry solvent solution, the co-non-solvent comprising at least one member selected from the group consisting of naphthenic oil, paraffinic oil, benzyl formate, and poly(propylene glycol). 14. The method according to claim 13, wherein a weight ratio of co-non-solvent to the CL-20 non-solvent is in a range of from about 5:95 to about 20:80. 15. The method according to claim 1, further comprising preparing the CL-20 from 2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo-[5.5.0.05,903,11] dodecane (TADA). 16. The method according to claim 1, further comprising, subsequent to separating, washing the precipitated epsilon polymorph CL-20 crystals with at least one member selected from the group consisting of isopropanol and ethanol, and washing the precipitated epsilon polymorph CL-20 crystals with water. 17. A method for crystallizing epsilon polymorph 2,4,6,8,10, 12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo [5.5.0.05,903, 11]-dodecane (CL-20), comprising: dissolving an amount of CL-20 into a solution containing a CL-20 solvent and water to form an aqueous phase and a wet CL-20 solvent phase, wherein the CL-20 is dissolved in the wet CL-20 solvent phase; substantially drying the wet CL-20 solvent phase to form a substantially dry solvent solution containing the CL-20; adding a base to the wet CL-20 solvent phase to neutralize acidic species; providing a crystallizer containing a CL-20 non-solvent; adding the substantially dry solvent solution to the crystallizer containing the CL-20 non-solvent to cause precipitation of epsilon polymorph CL-20 crystals by inverse precipitation technique; and separating the precipitated epsilon polymorph CL-20 crystals from the CL-20 non-solvent and the CL-20 solvent. 18. The method according to claim 17, wherein the base comprises at least one member selected from the group consisting of Na 2CO3, K2CO3 , NaHCO3, KHCO 3, NaOH, and KOH. 19. The method according to claim 17, wherein substantial drying the wet CL-20 solvent phase comprises azeotropic distillation to remove an azeotrope comprising water and the CL-20 solvent. 20. The method according to claim 19, wherein the dry solvent solution contains less than 1.5 weight percent water. 21. A method for crystallizing epsilon polymorph 2,4,6,8,10, 12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903, 11]-dodecane (CL-20), comprising: preparing a substantially dry CL-20 solvent solution containing an amount of CL-20 dissolved in a solvent; providing a crystallizer containing a CL-20 non-solvent and seed crystals of epsilon polymorph CL-20; adding the substantially dry CL-20 solvent solution to the crystallizer containing the CL-20 non-solvent and the seed crystals of the epsilon polymorph CL-20 to cause precipitation of epsilon polymorph CL-20 crystals by inverse precipitation technique; and separating the precipitated epsilon polymorph CL-20 crystals from the CL-20 non-solvent and the solvent. 22. The method according to claim 21, wherein preparing the substantially dry CL-20 solvent solution comprises substantially drying a wet CL-20 solvent solution containing the amount of CL-20 dissolved in the solvent. 23. The method according to claim 22, wherein substantially drying the wet CL-20 solvent solution comprises azeotropic distillation to remove an azeotrope comprising water and the solvent. 24. The method according to claim 21, wherein the substantially dry CL-20 solvent solution contains less than 1.5 weight percent water. 25. The method according to claim 21, wherein the solvent comprises at least one member selected from the group consisting of ethyl acetate, methyl acetate, isopropyl acetate, butyl acetate, tetrahydrofuran, and methyl ethyl ketone. 26. The method according to claim 21, wherein the solvent comprises ethyl acetate. 27. The method according to claim 21, wherein the solubility of CL-20 in the solvent is greater than 20 percent weight/volume (g/ml). 28. The method according to claim 21, wherein the CL-20 non-solvent is free of halogens. 29. The method according to claim 21, wherein the CL-20 non-solvent is free of chlorine. 30. The method according to claim 21, wherein the CL-20 non-solvent comprises at least one member selected from the group consisting of hexane, cycloheptane, heptane, octane, benzene, toluene, and xylene. 31. The method according to claim 21, wherein separating the precipitated epsilon polymorph CL-20 crystals from the CL-20 non-solvent and the solvent comprises filtration. 32. The method according to claim 21, wherein the precipitated epsilon polymorph CL-20 crystals comprise particles having maximum diameters of, on average, about 40 μ m to about 70 μm. 33. The method according to claim 21, further comprising adding a co-non-solvent to a wet CL-20 solvent solution or the substantially dry CL-20 solvent solution, the co-non-solvent comprising at least one member selected from the group consisting of naphthenic oil, paraffinic oil, benzyl formate, and poly(propylene glycol). 34. The method according to claim 33, wherein a weight ratio of co-non-solvent to CL-20 non-solvent is in a range of from about 5:95 to about 20:80. 35. The method according to claim 21, further comprising preparing the CL-20 from 2,6,8,12-tetraacetyl-2,4,6,8,10,12-hexaazatetracyclo-[5.5.0.05,903, 11]-dodecane (TADA). 36. The method according to claim 21, further comprising, subsequent to separating, washing the precipitated epsilon polymorph CL-20 crystals with at least one member selected from the group consisting of isopropanol and ethanol, and washing the precipitated epsilon polymorph CL-20 crystals with water.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (13)
Nielsen Arnold T. (Santa Barbara CA), Caged polynitramine compound.
Andrew J. Sanderson ; Kirstin Warner ; Robert B. Wardle, Process for making 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo[5.5.0.05,903,11]-dodecane.
Johnston Harold Eugene ; Wardle Robert B., Process of crystallizing 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12,-hexaazatetracyclo [5.5.0.0.5,903,11]- dodecane.
Voigt ; Jr. H. William (Stanhope NJ) Strauss Bernard (Rockaway NJ), Process of reducing shock sensitivity of explosive nitramine compounds by crystal modification.
Duddu Raja G. ; Dave Paritosh R., Processes and compositions for nitration of N-substituted isowurtzitane compounds with concentrated nitric acid at elevated temperatures to form HNIW and recovery of gamma HNIW with high yields and p.
Cannizzo Louis F. ; Edwards William W. ; Wardle Robert B. ; Highsmith Thomas K., Synthesis of 2,4,6,8,10,12-hexabenzyl-2,4,6,8,10,12-hexaazatetracyclo [5.5.0.05,9.03,11]dodecane.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.